Watson Pharmaceuticals Launches Generic Percocet(R) 7.5 Mg / 325 Mg and 10 Mg / 325 Mg - Company Exceeds Target With 14 Generic Product Launches Year-to-Date -



    CORONA, Calif., Oct. 20 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals,
 Inc. (NYSE:   WPI), a leading specialty pharmaceutical company, announced today
 that it has initiated shipments of oxycodone and acetaminophen (APAP) tablets
 in 7.5 mg / 325 mg and 10 mg / 325 mg strengths.  Oxycodone/APAP is the
 generic equivalent to Endo Pharmaceuticals' Percocet(R) tablets and is
 indicated for the relief of moderate to moderately severe pain.  For the
 12-months ending August 2003, Percocet(R) 7.5 mg / 325 mg and 10 mg / 325 mg
 had sales of approximately $157 million.
     (Logo:  http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO )
 
     About Watson Pharmaceuticals, Inc.
     Watson Pharmaceuticals, Inc., headquartered in Corona, CA, is a leading
 specialty pharmaceutical company that develops, manufactures, markets and
 distributes branded and generic pharmaceutical products.  Watson pursues a
 growth strategy combining internal product development, strategic alliances
 and collaborations and synergistic acquisitions of products and businesses.
 
     For press releases and other company information, visit Watson
 Pharmaceuticals' Web site at http://www.watsonpharm.com .
 
     Forward-Looking Statement
     Any statements contained in this press release that refer to future events
 or other non-historical facts are forward-looking statements that reflect
 Watson's current perspective of existing trends and information as of the date
 of this release.  Except as expressly required by law, Watson disclaims any
 intent or obligation to update these forward-looking statements.  Actual
 results may differ materially from Watson's current expectations depending
 upon a number of factors affecting Watson's business.  These factors include,
 among others, risks and uncertainties detailed in Watson's periodic public
 filings with the Securities and Exchange Commission, including but not limited
 to Watson's Annual Report on Form 10-K for the year ended December 31, 2002
 and its Quarterly Report on Form 10-Q for the quarters ended March 31 and June
 30, 2003.
 
     Percocet(R) is a registered trademark of Endo Pharmaceuticals, Inc.
 
 

SOURCE Watson Pharmaceuticals, Inc.

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.